Table 2.
Correlates of cardiac lesions, left ventricular hypertrophy, cardiac failure and valvular calcifications
| Parameters | Cardiaclesions | Leftventricularhypertrophy | Cardiacfailure | Valvular calcifications | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No | Yes | p | No | Yes | p | No | Yes | p | No | Yes | p | |
| N | 8 (17.8) | 37 (82.2) | 18 (40) | 27 (60) | 29 (64.4) | 16 (35.6) | 28 (62.2) | 17 (37.8) | ||||
| Male sex, n (%) | 4 (50) | 25 (67.6) | 0.427 | 12 (66.7) | 17 (62.9) | >0.999 | 20 (68.9) | 9 (56.3) | 0.518 | 17 (60.7) | 12 (70.6) | 0.541 |
| Age, years (SD) | 48.0 (10.0) | 53.7 (11.5) | 0.199 | 54.4 10.2) | 51.6 (12.1) | 0.425 | 50.1 (10.0) | 57.4 (12.5) | 0.039 | 48.4 (9.7) | 59.9 10.4) | 0.001 |
| Diabetemellitus, n (%) | 2 (25) | 12 /32.5) | >0.999 | 9 (50) | 5 (18.5) | 0.047 | 9 (31) | 5 (31.2) | >0.999 | 6 (21.4) | 8 (47) | 0.101 |
| Smoking, n (%) | 2 (25) | 8 (21) | >0.999 | 4 (22.2) | 6 (22.2) | >0.999 | 8 (27.6) | 2 (12.5) | 0.292 | 6 (21.4) | 4 (23.5) | >0.999 |
| Dyslipidemia, n (%) | 2 (25) | 13 (31.1) | 0.699 | 8 (44.4) | 7 (25.9) | 0.218 | 10 (34.5) | 5 (31.2) | >0.999 | 9 (31.1) | 6 (35.3) | >0.999 |
| Duration on dialysis [Q1-Q3] | 24 [14-42] | 30 [17-54] | 0.389 | 18 [10-38] | 41 [26-32] | 0.009 | 30 [16-45] | 34 [17-63] | 0.602 | 31 [16-60] | 29 [10-44] | 0.725 |
| History of cardiac lesions, n (%) | 6 (75) | 17 (45.9) | 0.435 | 7 (38.9) | 12 (44.4) | 0.766 | 10 (34.5) | 9 (56.2) | 0.212 | 11 (39.3) | 8 (47) | 0.757 |
| HIV, HBV or HCV, n (%) | 3 (37.5) | 9 (24.3) | 0.661 | 3 (16.7) | 9 (33.3) | 0.308 | 7 (24.1) | 5 (31.2) | 0.528 | 6 (21.4) | 6 (35.3) | 0.325 |
| IEC/ARA2 treatment, n (%) | 3 (37.5) | 21 (56.7) | 0.443 | 8 (44.4) | 16 (59.2) | 0.374 | 16 (55.2) | 8 (50) | 0.765 | 16 (57.1) | 8 (47) | 0.552 |
| SBP, mmHg (SD) | 137 (17) | 151 (19) | 0.094 | 145 (22) | 151 (21) | 0.331 | 148 (22) | 149 (21) | 0.908 | 146 (22) | 152 (19) | 0.384 |
| DBP, mmHg (SD) | 75 (19) | 77 (13) | 0.609 | 74 (14) | 79 (14) | 0.299 | 79 (14) | 74 (14) | 0.267 | 79 (14) | 74 (13) | 0.274 |
| BMI, kg/m2 (SD) | 24.0 (2.9) | 22.6 (3.5) | 0.293 | 23.0 (2.7) | 22.8 (3.8) | 0.916 | 23.6 (3.6) | 21.5 (2.7) | 0.044 | 23.4 (3.1) | 22.0 (3.8) | 0.199 |
| Interdialytic weight gain, kg (SD) | 3.4 (0.5) | 3.1 (0.9) | 0.281 | 3.1 (0.5) | 3.1 (1.0) | 0.976 | 3.3 (0.8) | 2.8 (0.8) | 0.059 | 3.3 (0.9) | 2.8 (0.7) | 0.047 |
| Hemoglobin level, g/dl (SD) | 10.4 (1.2) | 9.8 (1.4) | 0.338 | 10.5 (1.4) | 9.5 (1.3) | 0.022 | 10.1 (1.4) | 9.6 (1.5) | 0.311 | 9.8 (1.4) | 10.1 (1.3) | 0.484 |
| Total serum calcium, mg/dl | 8.5 (0.4) | 8.7 (1.0) | 0.733 | 8.8 (1.0) | 8.6 (0.9) | 0.506 | 8.7 (0.8) | 8.7 (1.2) | 0.925 | 8.5 (0.8) | 8.9 (1.2) | 0.152 |
| Serumphosphorus, mg/dl | 5.1 (1.7) | 4.5 (1.9) | 0.449 | 4.9 (1.8) | 4.3 (1.8) | 0.314 | 4.9 (2.0) | 4.1 (1.4) | 0.259 | 4.8 (1.9) | 4.3 (1.7) | 0.402 |
| Calcium-phosphate product, mg2/dl2 | 43.9 (15.0) | 38.5 (15.6) | 0.450 | 43.4 (16.1) | 36.3 (14.5) | 0.172 | 41.9 (17.1) | 35.0 (11.2) | 0.200 | 40.3 (16.0) | 38.2 (15.2) | 0.688 |
ACEI, Angiotensin Converting Enzyme Inhibitor; ARA, Angiotensin Receptor Antagonist; BMI, Body Mass Index; DBP, Diastolic Blood Pressure; HIV, Human Immunodeficiency Virus; HBV, Hepatitis B Virus; HCV, Hepatitis C Virus; Q1-Q3, 1st-3rd quartiles; SBP, Systolic Blood Pressure; SD, Standard Deviation